Claims

[Claim 1] ~~A~~Use ~~of pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising~~ (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient in the manufacture of a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, wherein the pharmaceutical composition is ~~substantially~~ free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof or comprises (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in a concentration of 0.03 part by weight or less per part by weight of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof .

[Claim 2] The ~~pharmaceutical composition~~ use of claim 1, wherein the pharmaceutical composition ~~which~~ is free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

[Claim 3] The ~~pharmaceutical composition~~use of claim 1 or 2, ~~which~~wherein the pharmaceutical composition does not substantially have mydriatic action.

[Claim 4] The ~~pharmaceutical composition~~use of any one of claims 1 to 3, wherein the myopia is axial myopia, refractive myopia, pseudomyopia, pathological myopia, simple myopia, extreme myopia, severe myopia, high myopia, moderate myopia, low myopia, myopia complicated by glaucoma, myopia

at the risk of the onset of glaucoma, or myopia with high intraocular pressure.

[Claim 5] The ~~pharmaceutical composition~~use of any one of claims 1 to 4, wherein the pharmaceutical composition is suitable for ocular topical administration.

[Claim 6] The ~~pharmaceutical composition~~use of claim 5, wherein the ocular topical administration is ophthalmic administration, administration by an ophthalmic ointment, conjunctival sac administration, intravitreal administration, subconjunctival administration, sub-Tenon's administration, conjunctival sac injection, or application to the eyelid.

[Claim 7] The ~~pharmaceutical composition~~use of any one of claims 1 to 6, wherein the pharmaceutical composition ~~which~~ is in the form of an eye drop, an eye gel, an ophthalmic ointment, or an injection.

[Claim 8] The ~~pharmaceutical composition~~use of any one of claims 1 to 7, wherein the concentration of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is 0.0001 - 5% (w/v).

[Claim 9] The ~~pharmaceutical composition~~use of any one of claims 1 to 7, wherein the concentration of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is 0.001 - 1% (w/v).

[Claim 10] The ~~pharmaceutical composition~~use of any one of claims 1 to 7, wherein the concentration of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is 0.001% (w/v) or more and less than 1% (w/v).

[Claim 11] The ~~pharmaceutical composition~~use of any one of claims 1 to 7, wherein the

concentration of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is 0.002 - 0.5% (w/v).

[Claim 12] The ~~pharmaceutical composition~~use of any one of claims 1 to 7, wherein the concentration of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is 0.002 - 0.01% (w/v).

[Claim 13] The ~~pharmaceutical composition~~use of any one of claims 1 and 3 to 12, wherein the concentration of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is less than ~~0.1~~0.05% (w/v).

[Claim 14] The ~~pharmaceutical composition~~use of any one of claims 1 and 3 to 13, wherein the concentration of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the pharmaceutical composition is ~~0.05~~0.01 part by weight or less per part by weight of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

[Claim 15] ~~A pharmaceutical composition for suppressing the axial length elongation, comprising~~Use of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient in the manufacture of a pharmaceutical composition for suppressing the axial length elongation, wherein the pharmaceutical composition is ~~substantially~~ free of (-)-11-[2-[2-

[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof or comprises (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in a concentration of 0.03 part by weight or less per part by weight of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

[Claim 16] ~~A pharmaceutical composition for suppressing the refractive error, comprising~~Use of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient in the manufacture of a pharmaceutical composition for suppressing the refractive error, wherein the pharmaceutical composition is ~~substantially~~ free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof or comprises (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in a concentration of 0.03 part by weight or less per part by weight of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

[Claim 17] Use of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the manufacture of an agent for treating and/or preventing myopia, wherein the agent is free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof or

comprises (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in a concentration of 0.03 part by weight or less per part by weight of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

~~[Claim 18] The use of claim 17, wherein the agent is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.~~

[Claim ~~19~~18] Use of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the manufacture of an agent for suppressing myopia progression, wherein the agent is free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof or comprises (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in a concentration of 0.03 part by weight or less per part by weight of (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

~~[Claim 20] The use of claim 19, wherein the agent is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acethyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.~~